Homepage Top Section2

The breakthrough therapy designation for the Keytruda, Lenvima combo is for the first-line treatment of patients with advanced unresectable HCC that is not responsive to locoregional treatment. Keytruda

The company said that the week 96 data from the two-cohort BRIGHTE trial revealed that fostemsavir continued to improve virologic suppression and immunologic response. Fostemsavir is a prodrug

In this regard, the company has submitted an extension application to the European Medicines Agency (EMA) for the subcutaneous use of daratumumab, co-formulated with recombinant human hyaluronidase PH20

As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be responsible for the development and commercialisation

Zejula achieved the primary endpoint of the PRIMA trial by showing a statistically significant improvement in progression-free survival irrespective of the participating women’s biomarker status, in comparison to

As per terms of the deal, Galapagos will secure $3.95bn (£3.5bn) upfront payment and $1.1bn (£874m) equity investment from Gilead. It intends to use the proceeds to expand

Nexus has entered into an agreement with Wisconsin’s village Pleasant Prairie for the development of a sterile injectable manufacturing facility. Expected to be completed in 10 years, the

Velocity Pharmaceutical Development, along with Dr John Nestor, had established Spitfire for the development of SP-1373, a potent GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH). Under the

The option obtained by MorphoSys gives it the rights to globally develop and commercialise Vivoryon’s family of QPCTL inhibitors, including the latter’s lead compound PQ912. Currently, PQ912 had